About

Bert-Arjan Millenaar, CEO and founder of NLC, went through this first-hand. His experience proves why NLC is an essential company that significantly impacts society every day.

In May 2014, Bert-Arjan became the proud father of a little girl. Unfortunately, she was born prematurely, leaving him helpless next to her incubator. He desperately wanted nothing more than to hold his little girl and bring her home. At the time, Bert-Arjan didn’t know that a professor across the country was working on an invention that could have prevented his pain. A lack of entrepreneurship and network kept the professors’ innovation (Concord Neonatal) out of our healthcare system. Unfortunately, this is just one of many stories with the same plot: a patient is in critical need of equipment that has not yet been brought to the market.

We at NLC have made it our mission to change this.

We find inventions, select the most promising ones, and build them into viable healthtech ventures to advance health.

Since 2015, NLC has evaluated thousands of inventions and built over 100 ventures. We have a great team of dedicated employees and industry experts (+3000 individuals) who enable us to continue our mission daily. We guarantee that you are in safe, trustworthy hands!

Together we are building ventures and advancing health for patients worldwide. In addition, we are an experienced fund manager that makes healthcare innovation investible for retail and institutional investors.

HOW DO WE ACHIEVE SUCCESS? THROUGH ENTREPRENEURSHIP AT SCALE!

We strongly believe that the most successful way to bring more healthtech inventions to patients is by using entrepreneurship at scale. Entrepreneurship is essential to get a venture through the early stages, and this is where you need to put in the hard work on many levels simultaneously. The dedication of the CEOs and their team is crucial to getting the venture to the market successfully.

By building ventures at scale, we can benefit from the data and learnings we’ve harvested along the way. We know the pitfalls. We know the shortcuts. We try hard, and if we fail, we fail fast. To support a venture, we build teams around it that know what it takes to make a venture successful. We surround our CEOs with expertise and support in all areas, from helping to secure finance, providing advice on patents and certifications, training the team on sales, and everything in between.

OUR NETWORK

Our network is essential to us and plays a crucial role in our journey to success. Committed specialists worldwide support our team through our venture-building process.

We partner with 4 groups of people, and together we strive for success!

  1. Inventors and research institutes that want to bring their inventions to the market with us,
  2. Medical, technical and business specialists that help us evaluate the inventions,
  3. Investors that are willing to take the risk and invest in early seed start-ups,
  4. Entrepreneurs and advisors that help us grow the ventures we have built.

Together, we overcome fragmentation so we can build ventures and advance health.

HOW DO WE HELP YOU LOWER YOUR RISK CURVE?

NLC operates at the beginning of the risk curve, where the risk is high, and the invested capital is relatively low. This opens the opportunity for us to make an impact by utilising our entrepreneurship at scale to lower the risk curve of our ventures. Our ventures are de-risked at a faster rate with low(er) costs, which scales NLC’s portfolio further (statistically) and de-risks our model.

This means fewer risks and more rewards!

Similar companies

EM

EMCIFund

Address the critical bottlenecks in both established and emerging markets that limit access and affordability to novel cancer solutions. Inculcate the tenets of ESG (Environmental, Social and Governance) based investing and measure the progress and impact of our portfolio using the following metrics: E: The ability to optimize differential drug and device pricing based on geography and expand access to promising products early in their lifecycle S: Ability to boost R&D productivity through operational optimization and process transformation G: Promote ethical conduct of business and collaboration while ensuring inclusion & diversity What We DoInvest in US and EU based cancer start-ups who are keen to explore emerging markets or engage in collaborative R&D. Streamline the product-market fit and ensure access to supportive infrastructure and resources. Facilitate their collaborative R&D/commercialization strategy in geographies of interest. How We Do It Accelerate the path to successful commercialization for US and EU based start-ups developing the next generation of oncology solutions by: Reducing costs through infrastructure consolidation and collaborative expertise Expanded access to capital Facilitating rapid market penetration and commercial scaling​

BR

BrightEdge

BrightEdge propels groundbreaking patient-centric solutions by investing in and supporting the most innovative startup companies to advance science, reduce disparities, and promote healthcare sustainability. BrightEdge is the innovation, impact investment, and venture capital arm of the American Cancer Society (ACS). Through our donor-funded ACS Impact Venture Fund (AIVF), we further ACS’s mission by investing in for-profit, early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, devices, and technologies to fuel and accelerate our vision of ending cancer as we know it, for everyone. About BrightEdge and The American Cancer Society BrightEdge is helping create a stream of alternate income to sustain the critical work being done across our pillars. Donations to BrightEdge become a sustainable source of financial support to the American Cancer Society, diversifying and modernizing the ACS’s income sources. Investment returns from the AIVF portfolio are both reinvested in AIVF to further support new and existing companies in the portfolio and additional proceeds are used to sustain ACS’s lifesaving programs in research, access, and health equity. BrightEdge investment decisions and innovation programming are guided by the mission priorities of ACS and seek to achieve mission-driven social impact through its proprietary Cancer Impact Investment FrameworkTM (CIIFTM). BrightEdge builds on the American Cancer Society’s commitment to funding and conducting cancer research and plays a key role in accelerating today’s most promising oncology-focused technologies. Our ability to translate scientific discoveries into accessible cures and solutions depends on investments in entrepreneurial for-profit companies that can validate, develop, and commercialize products and services at scale in the healthcare marketplace for people facing cancer. BrightEdge plays a unique role alongside traditional venture capital firms by addressing early-stage funding gaps, incubating high-impact companies, bringing system-level knowledge to companies at critical points in product development, and helping emerging companies access world-class intellectual and human capital as they grow. Learn how BrightEdge will help improve 1.5 million lives by investing in cancer-focused therapies and technologies in its most recent annual report and infographic.

HB

H7 BioCapital

Headquartered in Silicon Valley, H7 BioCapital is a global venture platform that supports the transformational growth of healthcare companies through its influential venture capital financing, global accelerator program, venture club, VC class, webinars, conferences and other strategic events, and connect them with investors, scientists, physicians, corporate partners and other industrial professionals to jointly build a resource - rich healthcare innovation ecosystem. H7 BioCapital consists of three parts of organizations: H7 Accelerator, H7 Venture, and H7 Café to support the transformational growth of healthcare by striving to be transformational itself. Need a boost with your healthcare startup? Let H7 be your support - Health, Heal, Happiness, Hope, Humanity, Home and Holistic! H7 Accelerator 3-month-long cohort-based healthcare accelerator program providing mentorship, funding and other support to early-stage biotech, medtech and device startups along with a lifelong network for these leaders and innovators. H7 Venture Investment platform providing early stage funding support to healthcare startups that are believed to have a long-term growth potential. H7 Café A high-quality startup community that supports the growth of healthcare entrepreneurs by frequent events such as networking, educational workshop, private deal flow meetings and other programs to connect the corporate, scientists, investor and founder ecosystem.

HS

Healthcare Shares

We’re a team of entrepreneurs and venturers building a community of healthcare professionals invested in healthcare innovation. We know what it takes to build successful companies, and we use that knowledge to supercharge a portfolio of clinician and practitioner founders tackling the biggest challenges and taking advantage of the biggest opportunities in healthcare. We are exclusively focused on healthcare. The majority of our investors are healthcare professionals and clinicians and all of our startups are focused on healthcare. We know how hard healthcare is and we are here to help. Physicians have backed us from the start. Our CEO & Founder, Laurence Girard, successfully raised over $24M in capital from more than 500 physician investors who invested in Fruit Street Health, his telemedicine startup. Many of these physicians were the founding investors in Healthcare Shares. We know what it is like to raise capital from healthcare professionals at scale. We are focused on social impact. By listing your company on Healthcare Shares, you are working with a company this is not just focused on profit, but one that is actually having a social impact in healthcare. We’ve created a network of investors who advise entrepreneurs. By investing in campaigns on Healthcare Shares, you can be an evangelist for your investment and provide advice to the entrepreneurs innovating the products that you believe in. We market campaigns through our network of thousands of clinicians. Many crowdfunding platforms expect entrepreneurs to do all the marketing work, but we actively advertise their campaigns on platforms like LinkedIn and throughout our clinician network.

SG

SGInnovate

The world has hard problems to solve, and answers are urgently needed. We help entrepreneurs on a mission to solve these hard problems build companies. We believe Singapore has the resources and capabilities to tackle the pressing challenges impacting people around the world. SGInnovate has been established to help these ambitious and capable people to build 'technology-intensive' products borne out of scientific research, leveraging the full power of the Singapore ecosystem to achieve this mission. Investment Capital Singapore has over $1b+ of private-market funds and another $1b+ of public-sector funds. Government Singapore remains one of the most attractive and trusted places to build companies, in large part due to our economic competitiveness, as well as political and operational stability. Research A global research and innovation hub, S$25B has been committed to Singapore's latest Research, Innovation and Enterprise (RIE) five-year plan, covering domains such as healthcare, sustainability and manufacturing, through to 2025. Corporate Backing Singapore brings together over 7000 regional and global corporations who represent go-to-market help, joint product development, investment funding and possible exits. World Class Institute of Higher Learning Singapore is home to two of the top 20 globally-ranked universities.

KV

KHP Ventures

We’re a small team of investors, entrepreneurs, operators, clinicians, scientists and technologists, supported by our Board of healthcare and life sciences leaders and an Investment Committee of experienced venture investors and innovators. Together the partners represent one of the largest teaching hospital systems in the UK and Europe, serving a diverse local population. Their vision is to support world-leading healthcare ecosystem that drives new frontiers in modern medicine with synergistic integration of healthcare, academia, innovation and private capital.